Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Quadrosilan
Другие языки:

Quadrosilan

Подписчиков: 0, рейтинг: 0
Quadrosilan
Quadrosilan.svg
Clinical data
Trade names Cisobitan
Other names Quadrosilane; KABI-1774; 2,6-cisdiphenylhexa-
methylcyclotetrasiloxane
Drug class Nonsteroidal estrogen
Identifiers
  • 2,2,4,6,6,8-hexamethyl-4,8-diphenyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C18H28O4Si4
Molar mass 420.758 g·mol−1
3D model (JSmol)
  • C[Si]1(O[Si](O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C)(C)C3=CC=CC=C3)C
  • InChI=1S/C18H28O4Si4/c1-23(2)19-25(5,17-13-9-7-10-14-17)21-24(3,4)22-26(6,20-23)18-15-11-8-12-16-18/h7-16H,1-6H3
  • Key:ZTQZMPQJXABFNC-UHFFFAOYSA-N

Quadrosilan (INN, BAN) (brand name Cisobitan; former developmental code name KABI-1774) is a synthetic nonsteroidal estrogen that was developed in the 1970s and that is or has been used as an antigonadotropic agent in the treatment of prostate cancer. It is an organosilicon compound, and is also known as 2,6-cisdiphenylhexamethylcyclotetrasiloxane. Quadrosilan has estrogenic activity equivalent to that of estradiol, and can produce feminization and gynecomastia as side effects in male patients.

See also


Новое сообщение